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ABSTRACT 
The utilization of nanotechnology in medicine and all the more explicitly tranquilize conveyance is resolved to spread quickly.Right now 
numerous substances are under scrutiny for medication conveyance and all the more explicitly for disease treatment Strangely pharmaceutical 
sciences are utilizing nanoparticles to lessen lethality and reactions of medications and up to as of late did not understand  that bearer 
frameworks themselves may force dangers to the patient.The sort of risks that are presented by utilizing nanoparticles for medication 
conveyance are past that presented by customary perils forced by synthetic concoctions in established conveyance frameworks. For 
nanoparticles the learning on molecule danger as got in inward breath poisonous quality tells the way the best way to examine the potential 
risks of nanoparticles. The toxicology of particulate issue contrasts from toxicology of substances as the making chemical(s)  could conceivably 
be dissolvable in natural frameworks, therefore impacting extraordinarily the potential presentation of different inside organs. This may differ 
from a fairly high neighborhood introduction in the lungs and a low or neglectable presentation for other organ frameworks after inward 
breath. Be that as it may, ingested species may likewise impact the potential harmfulness of the breathed in particles. For n anoparticles the 
circumstance is distinctive as their size opens the potential for intersection the different organic boundaries inside the body. From a positive 
perspective, particularly the possibility to cross the blood cerebrum hindrance may open new ways for medication conveyance into the mind. 
Likewise, the nanosize additionally takes into consideration access into the cell and different cell compartments including the core. A large 
number of substances are right now under scrutiny for the arrangement of nanoparticles for medication conveyance, differing from organic 
substances like egg whites, gelatin and phospholipids for liposomes, and more substances of a concoction nature like different polymers and 
strong metal containing nanoparticles. Clearly the potential communication with tissues and cells, and the potential harmfulness, significantly 
relies upon the real creation of the nanoparticle plan. This paper gives a diagram on a portion of the right now utilized fra meworks for 
medication conveyance. 
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INTRODUCTION 
Targeted drug delivery is a method of delivering medication 
to a patient in a manner that increases the concentration of 
the medication in some parts of the body relative to others. 
Targeted drug delivery seeks to concentrate the medication 
in the tissues of interest while reducing the relative 
concentration of the medication in the remaining tissues. 
This improves efficacy.(1) The ultimate goal of drug delivery 
research is to help patients by developing clinically useful 
formulations. During the last several decades controlled 
drug delivery technology has advanced significantly, leading 
to the development of various clinical formulations 
improving patient compliance and convenience. Current 
technologies allow delivery of drugs at desired release 
kinetics for extended periods of time ranging from days to 
years. Oral & transdermal drug delivery systems routinely 
deliver drugs for 24hrs, substantially improving drug 
efficacy & minimizing side effects. Implantable systems can 
locally deliver drugs for months, even years. While 
significant advances have been made, there are still areas 
where substantial improvements need to be made to reach 
the next level of clinical relevance. One such area is targeted 
drug delivery to solid tumors. The clinically significant 
impact of targeted drug delivery lies in the ability to 
specifically target a drug or drug carrier to minimize drug-
originated systemic toxic effects.(3) Drug targeting is the 
delivery of drugs to receptors or organs or any other specific 
part of the body to which one wishes to deliver the drugs 
exclusively. The drug’s therapeutic index, as measured by its 
pharmacological response and safety, relies in the access 
and specific introduction of the drug with its candidate 
receptor, whilst minimizing its introduction with non –target 
tissue. The desired differential distribution of drug its 
targeted delivery would spare the rest of the body and thus 
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significantly reduce the overall toxicity while maintaining its 
therapeutic benefits The targeted or site- specific delivery of 
drugs is indeed a very attractive goal because this provides 
one of the most potential ways to improve the therapeutic 
index of the drugs.(1)NPs have a relatively large (functional) 
surface which is able to bind, adsorb and carry other 
compounds such as drugs, probes and proteins. However, 
many challenges must be overcome if the application of 
nanotechnology is to realize the anticipated improved 
understanding of the patho-physiological basis of disease, 
bring more sophisticated diagnostic opportunities, and yield 
improved therapies. (2) 
1.1 CLASSIFICATION OF TARGETED DRUG 
DELIVERY. 
 Systemic targeting based on blood circulation and 
extravasation a). Ligand–receptor interaction mediated 
b). Locally-activated delivery 
i). Self-triggered release of the drug at the target cells 
ii). Externally-activated release of the drug at the target cells 
 Intracellular targeting 
a). Low-pH activation technologies that use default pathway 
delivery to lysosomes b). Mechanisms that avoid (default) 
lysosomal delivery.(3) 
The past few decades, there has been a considerable 
research interest in the area of drug delivery using 
particulate delivery systems as carriers for small and large 
molecules. Particulate systems like nanoparticles have been 
used as a physical approach to alter and improve the 
pharmacokinetic and pharmacodynamic properties of 
various types of drug molecules. They have been used in-vivo 
to protect the drug entity in the systemic circulation, restrict 
access of the drug to the chosen sites and to deliver the drug 
at a controlled and sustained rate to the site of action. 
Various polymers have been used in the formulation of 
nanoparticles for drug delivery research to increase 
therapeutic benefit, while minimizing side effects.(4) 
1.2 ADVANTAGES 
1. Particle size and surface characteristics of nanoparticles 
can be easily manipulated to achieve both passive and 
active drug targeting after parenteral administration. 
2. They control and sustain release of the drug during the 
transportation and at the site of localization, altering 
organ distribution of the drug and subsequent clearance 
of the drug so as to achieve increase in drug therapeutic 
efficacy and reduction in side effects. 
3. Controlled release and particle degradation 
characteristics can be readily modulated by the choice of 
matrix constituents. Drug loading is relatively high and 
drugs can be incorporated into the systems without any 
chemical reaction; this is an important factor for 
preserving the drug activity. 
4. Site specific targeting can be achieved by attaching 
targeting ligands to surface of particles or use of 
magnetic guidance. 
5. One fundamental advantage of nanoparticles with regard 
to other colloidal drug delivery systems (liposomes, 
niosomes, microemulsions etc.) and a fortiori to 
nanoemulsions, is their great kinetic stability and rigid 
morphology. 
6. The system can be used for various routes of 
administration including oral, nasal, parenteral, intra 
ocular etc. 
7. The Drug loading efficiency of nanoparticles is more than 
other targeted drug delivery systems. 
1.3 LIMITATIONS 
1. Their small size and large surface area can lead to 
particle aggregation, making physical handling of 
nanoparticles difficult in liquid and dry forms. 
2. In addition, small particles size and large surface area 
readily result in limited drug loading and burst release. 
These practical problems have to be overcome before 
nanoparticles can be used clinically or made 
commercially available. 
3. Sometime special storage conditions require. Example: 
PCL nanoparticle required to be stored at low temp. 
Because at higher temperature it get soften and loses 
its shape. 
4. Special instrument require like freeze dryer for solvent 
evaporation, centrifugation for nanoparticle 
separation. 
5. High pressure induced drug degradation. 
6. Coexistance of several colloidal species.(5) 
1.4 TYPE OF NANOPARTICLES 
According to the structural organization biodegradable 
nanoparticles are classified as nanocapsule & 
nanosphere. The drug molecules are either entrapped 
inside or adsorbed on the surface. 
According to material used for synthesis of nanoparticle five 
types of particle are: 
a. Polymeric Nanoparticle 
b. Solid Lipid Nanoparticle 
c. Pegylated Nanoparticle 
d. Magnetic Nanoparticle 
e. Metallic Nanoparticle 
Polymeric Nanoparticle 
Polymeric nanoparticles are nanoparticles which are 
prepared from polymers. The drug is dissolved, entrapped, 
encapsulated or attached to a nanoparticles and depending 
upon the method of preparation, nanoparticles, nanospheres 
or nanocapsules can be obtained. Some of the polymeric 
materials are used for synthesis like Cellulosic, Poly (vinyl 
alcohol), Poly (acrylic acid), Polyacrylamide, Poly capro 
lactone(6) 
The selection of the appropriate method for the preparation 
of nanoparticles depends on the physicochemical 
characteristics of the polymer and the drug to be loaded. The 
methodologies are classified as follows 
1.5 PREPARATION METHODS OF POLYMERIC 
NANOPARTICLES 
There are several methods on the preparation of polymeric 
nanoparticles and incorporation of bioactive compounds 
into them. In general, one of the two principles methods is 
utilized: controlled precipitation or controlled dispersion of 
the polymer. Few of the popular methods include solvent 
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displacement, salting-out, emulsion-solvent-evaporation, 
emulsion-solvent- diffusion and supercritical fluid 
technology. 
1.5.1 Solvent displacement method 
It is the simplest method compare to other methods, the 
polymer is dissolved in a good solvent that maybe partially-
polar and water-miscible solvent such as ethanol or acetone. 
When the drug is to be incorporated into the particles, it can 
be dissolved in the same phase along with the polymer. This 
polymer phase is introduced into a non-solvent aqueous 
phase containing a stabilizer (generally a hydrophilic 
surfactant) at a controlled rate under continuous mixing. As 
the partially-polar solvent diffuses rapidly into the aqueous 
phase (i.e. as the partially-polar phase is displaced by the 
polar phase), the polymer starts precipitating due to changes 
in its solubility, resulting in the formation of nanoparticles. 
The surfactant present in the aqueous phase helps in 
preventing particle aggregation. Choice of a 
drug/polymer/solvent/non-solvent system is the major 
limitation of this method and hence its applicability is 
confined to hydrophobic drugs and polymers.(7)
 
 
 
Figure 1: Schematic representation of the solvent displacement technique 
 
1.5.2 Salting out method 
Salting out technique is generally used for the preparation of 
drug-loaded biodegradable nanoparticles. This method was 
first applied to pseudolatexes.(7) It is based on the separation 
of water-miscible solvent from aqueous solutions by a 
salting out effect. An o /w emulsion is formed by adding a 
solution of the polymer and the drug in a water miscible 
solvent into an aqueous gel containing a salting-out agent 
and a colloidal stabilizer. Water is added to dilute this 
mixture, as a result of which nanoparticles are formed. 
Solvent and salting-out agents are then removed by cross-
flow filtration. The use of this method results in a very high 
loading efficiency along with high yield and also the scale-up 
is fairly easy, but this method can only be used for the 
loading of lipophilic drugs.
 
 
Figure 2: Schematic representation of the salting out technique 
1.5.3 Emulsification-solvent-evaporation 
It is based on the formation of a biphasic (o/w or w/o) or 
triphasic ( w / o /w or o/w/o) emulsion.(6) Generally, a 
preformed polymer is dissolved in an organic solvent which 
is water immiscible along with the drug, and is emulsified in 
an aqueous solution (o/w emulsion). The formed emulsion is 
then exposed to high energy mixers (e.g. high-speed or high-
pressure homogenizers, colloidal mills or ultra-sonic 
devices) to reduce globule size. The organic solvent is 
removed either by using heat or vacuum or even both at 
times. Nanoparticles are obtained as fine aqueous 
dispersions which can be collected and purified. The process 
variables involved in this method are complex and manifold, 
and the nanoparticles obtained are often polydisperse. 
However, this method is very popular for preparing 
polymeric microparticles rather than nanoparticles, as it 
facilitates industrial applicability and scalability.
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Figure 3: Schematic representation of the solvent-
evaporation technique. 
1.5.4 Emulsion-solvent-diffusion method 
It is another method which is used for nanoparticles 
preparation. It is a modified salting-out technique and differs 
mainly in the organic solvent which is partially miscible with 
water in this case.(8) This solvent is pre-saturated with water 
to achieve initial thermodynamic equilibrium between water 
and the organic phase. Solvent diffuses out upon addition of 
water and results in the formation of nanoparticle 
suspension. Controlled complexation induced by 
electrostatic interactions between oppositely charged 
polymers can yield stable colloidal dispersions. The 
interacting polymers could be therapeutically active (e.g. 
oligonucleotides and plasmid DNA) or may have tailored 
properties (e.g. pH-sensitivity).(9,10) A wide variety of Charge 
bearing polymers can be utilized to manufacture composite 
nanoparticles and varying physico-chemical properties.(11) 
 
Figure 4: Schematic representation of the 
emulsification/solvent diffusion technique 
1.5.5 Supercritical fluid technology 
It is an emerging science for the production of micro and 
nanoparticles. In this method, an organic liquid solution of 
the polymer and the active moiety is sprayed through a 
nozzle into a chamber containing a gas that is miscible with 
the solvent, but in which the polymer and the active 
compound are not soluble. The gaseous phase in this case is a 
super critical fluid (e.g. supercritical C02). The dispersion of 
the liquid solution in such a condition generates a high 
degree of super-saturation, leading to the formation of fine, 
uniform colloidal particles. The particles can be recovered 
from the solution by depressurizing the chamber and 
allowing the gas to escape.(12-15) 
1.5.6 Emulsion polymerization method 
The most popular example for this method of synthesis is the 
nanoparticles made from poly(methylmethacrylates), 
poly(alkylcyanoacrylates) and poly(methylidenemalonates). 
(15) Generally, a water insoluble monomer is dispersed in an 
aqueous medium containing a colloidal stabilizer, and the 
polymerization is induced and controlled by the addition of a 
chemical initiator or by variations in physical parameters 
such as pH or radiation. Both hydrophilic and lipophilic 
drugs can be entrapped in the polymeric wall when added to 
the polymerization medium or adsorbed on preformed 
particles. While each of the above mentioned nanoparticle 
preparation method has its advantages and disadvantages, 
they can all be fine-tuned to encapsulate variety of drugs. 
The literature evidence shows that the nanoparticles are 
mostly employed to incorporate hydrophobic drugs, simply 
because the majority of the techniques facilitate 
encapsulation of lipophilic compounds with very high 
loading (approximately up to 40% by weight) and capturing 
efficiencies (nearly 100%). When hydrophilic drugs are to be 
incorporated, in situ polymerization or complexation 
remains the most accepted method. The collective 
advancements in nanotechnology and engineering sciences 
are expected to contribute major breakthroughs for bulk 
manufacturing of polymeric nanoparticles. In the highly 
competitive pharma/biotech industry, the formulation 
scientist can concentrate towards development of novel 
products, irrespective of complexities involved in the 
procedures. As in most cases, majority of the scaleup issues 
can be addressed and solved with the help of parallel 
advancements in high-technology engineering. 
1.6 CHARACTERIZATION OF NANOPARTICLES 
1.6.1 Particle size 
Most of the properties of nanoparticle like drug loading and 
release pattern , in vivo distribution, tissue targeting, toxicity 
and biological fate are concerned with the size and size 
distribution of Nanoparticles so they had become an 
important parameter in characterization of product. It has 
been reported that micro particles are less effective drug 
delivers than particle having size ranging in between 
nanometers for e.g Nanoparticles having size range greater 
than 230 nm acquire in the spleen shown by body 
distribution  studies.(16)  Drug release is depend upon surface 
area larger the surface area more is the diffusion and less the 
surface area less is diffusion and surface area depend upon 
particle size i.e smaller the size greater is the surface area 
and vice –versa. Also large particle has large core which fills 
more drug and they diffuse out slowly. (17) It has been seen 
that aggregation occurs with small particle size. So it was 
considered that large particles will assist fast drug release 
and polymer degradation. (19) 
Method of determining particle size is by (19) 
1. Photon-correlation spectroscopy. 
2. Dynamic light scattering. 
3. Brownian motion and light scattering properties. 
4. Scanning or transmission electron microscopy (SEM or 
TEM). 
1.6.2 Surface Properties Of Nanoparticles 
The nature and intensity of the surface charge of 
nanoparticle is very important as it determine their 
interaction with its biological environment as well as their 
electrostatic interaction with bioactive compounds. After the 
intravenous administration of nanoparticles, body immune 
system recognizes these, followed by phagocytic removal 
from body by blood circulation. After the recognization by 
body, delivered to the mono nuclear phagocytes system 
(MPS) of body which degrade them .The MPS system of body 
involves parts such as liver, spleen, lungs and bone marrow. 
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And if once, surface non-modified nanoparticles 
(conventional nanoparticles) reached in the blood stream 
they undergo  rapid opsonization and cleared by the 
macrophages of MPS rich organs. (20) 
Phagocytes can be prevented by- 
(1) Coating the surface of nanoparticles with by using 
hydrophilic polymers/surfactants which coat the 
surface of nanoparticle. 
(2) With the help of biodegradable copolymers having 
hydrophilic segments like polyethylene glycol (PEG), 
polyethylene oxide, poloxamine and polysorbate 80 
(Tween 80) which are used to prepare Nanoparticles. 
For the characterization of surface property of 
nanoparticle determination of zeta potential is 
commonly employed.(21) Zeta  potential  reflects the 
electrical potential hold by particle and factor which 
affect its value are composition of particle and solvent 
in which it is dispersed. 
1.6.3 Drug loading (22) 
A high drug- loading capacity is the measure of successful 
nanoparticulate system because it reduces the amount of 
matrix material for administration. Drug loading can be done 
by two methods: 
a) Incorporation method: - In this drug is incorporated 
during the formation of nanoparticle. 
b) Adsorption/absorption method: - In this method drug 
is made to be adsorbed on nanoparticle. In this formed 
nanoparticle is kept in concentrated solution of drug 
and adsorption phenomenon take place. 
1.6.4 Drug release 
Another Factor for a formulation of successful 
nanoparticulate system, study of parameter such as both 
drug release profile and polymer biodegradation is concern. 
In general, drug release rate depends on: 
(a) Solubility of drug. 
(b) How far the Drug is diffused through the nanoparticle 
matrix. 
(c) Combination of erosion/diffusion process. 
(d) Degree of material matrix erosion/degradation and 
(e) Time taken by the drug for desorption through surface. 
Loading of drug by incorporation method produce system 
which has small burst effect and good sustained release 
characteristics. (23) Coating the nanoparticle with polymer, 
release is affected by movement of drug from core across the 
polymeric membrane. In this case polymeric membrane 
becomes release determing factor because it affects the 
solubility and diffusivity of drug. A number of methods can 
be used to determine in vitro release of drug 
(24,25)
.
 
(a) Reverse dialysis bag technique 
(b) Dialysis bag diffusion technique. 
(c) centrifugal ultra-filtration techniques 
(d) Agitation. 
(e) Using biological or artificial membrane i.e. Side-by-side 
diffusion of cells. 
1.6.5 Stability Study 
The stability study of optimized formulation was carried out 
as per ICH (International Conference on Harmonization) 
guidelines at 4° C and at room Temperature for  three 
months. Samples were withdrawn monthly and were 
determined for drug content by the method discussed 
previously in entrapment efficiency section.(26)
 
Table 1: Methods used in Characterization of Nanoparticless 
S.No PARAMETER CHARACTERIZATION METHODS 
1 Yield / Nanoparticle recovery Chemical drug assay employing a suitable UV spectrophotometric (or) HPLC method. 
2 Drug incorporation efficiency 
3 Surface morphology Scanning electron microscopy (SEM), Transmission electron microscopy (TEM), 
Atomic force microscopy  (ATM), Photon correlation spectroscopy (PCS), Laser 
defractometry& Mercury porositometry. 
4 Particle size & size distribution 
5 Surface charge Laser Doppler Anemometry (Zeta potentiometer). 
6 Residual solvent X-ray photoelectron spectroscopy (XPS) or Gas Chromatography (GC). 
7 Ease of reconstitution Particle aggregation studies on the basis of a numerical scale. 
8 Intravenous admixture studies Visual inspection for physical changes such as precipitation and pH determination. 
9 Sterility Sterility testing method as per IP 1996. 
10 Drug stability As per ICH Tripartite Guidelines. 
11 Targeting potential In-vivo tissue distribution studies in an animal model (rat). 
 
Drugs incorporated into nano particles for targeted drug delivery 
Table 2: List of Drugs incorporated in Nanoparticles (NPs) 
Drug Class Target organ/cells Technology References 
Camptothein(26) Chemotherapeutic Solid tumour PEG – PLA nano particles G.Maruthi(2011) 
Paclitaxel(28) Chemotherapeutic Arterial neoinlima Albumin nano particles Shikanov A(2004) 
SN-38(29) Chemotherapeutic Tumour Crystalline nano particles YunHwan ju(2011) 
Indinavil(26) Antiviral Brain Crystalline nano particles G.Maruthi(2011) 
Doxorubicin(30) Chemotherapeutic Brain Poly sorbate coated nano particles Robhash Kusam 
Subedi(2011) 
Itraconazole(31) Antifungal Macrophages Crystalline nano particles A.A badawi(2011) 
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